Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $19.11.

ATEC has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a report on Thursday, August 1st. Barclays assumed coverage on Alphatec in a report on Monday, July 8th. They set an “overweight” rating and a $19.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Alphatec in a research report on Thursday, August 1st. Piper Sandler dropped their price target on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Finally, Wells Fargo & Company lowered their price objective on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st.

Alphatec Stock Performance

ATEC opened at $6.55 on Thursday. The business’s 50-day moving average price is $10.30 and its two-hundred day moving average price is $12.58. Alphatec has a 1 year low of $5.74 and a 1 year high of $17.34. The company has a market capitalization of $916.24 million, a price-to-earnings ratio of -4.40 and a beta of 1.40. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.49.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The firm had revenue of $145.57 million during the quarter, compared to analyst estimates of $144.55 million. Alphatec had a negative net margin of 33.48% and a negative return on equity of 816.57%. The business’s revenue for the quarter was up 24.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.43) EPS. Equities analysts expect that Alphatec will post -1.04 EPS for the current fiscal year.

Insider Transactions at Alphatec

In other news, General Counsel Tyson Eliot Marshall sold 50,232 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $10.88, for a total transaction of $546,524.16. Following the completion of the transaction, the general counsel now directly owns 245,638 shares in the company, valued at $2,672,541.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 22.80% of the company’s stock.

Institutional Trading of Alphatec

Several institutional investors have recently modified their holdings of ATEC. First Light Asset Management LLC grew its stake in shares of Alphatec by 97.0% in the fourth quarter. First Light Asset Management LLC now owns 5,976,851 shares of the medical technology company’s stock worth $90,310,000 after purchasing an additional 2,943,310 shares during the last quarter. Cerity Partners LLC bought a new stake in shares of Alphatec in the fourth quarter worth $28,451,000. Artisan Partners Limited Partnership bought a new stake in shares of Alphatec in the fourth quarter worth $19,050,000. Goldman Sachs Group Inc. boosted its position in Alphatec by 93.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,451,499 shares of the medical technology company’s stock valued at $21,932,000 after acquiring an additional 702,950 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Alphatec by 48.1% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,125,042 shares of the medical technology company’s stock valued at $29,305,000 after acquiring an additional 690,022 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.